Xiaofan Lu
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
-
- Ferroptosis and cancer prognosis
- Respiratory Support and Mechanisms
Papers in
-
- Ferroptosis and cancer prognosis 10
- Renal cell carcinoma treatment 6
-
- Cancer-related molecular mechanisms research 5
- Co-authors
- Fangrong Yan (45 shared papers)Yang Wang (14 shared papers)Taige Chen (7 shared papers)Jun Wang (6 shared papers)Jialin Meng (22 shared papers)Liyun Jiang (14 shared papers)Yujie Zhou (16 shared papers)Bing Zhang (6 shared papers)
- Journals
- Clinical and Translational Medicine (4 papers)Cell Proliferation (2 papers)Critical Care (2 papers)Blood (2 papers)Nature Communications (2 papers)
- Partner nations
- ChinaUnited StatesFrance
In The Last Decade
Xiaofan Lu
64 papers receiving 1.5k citations
Xiaofan Lu's Hit Papers
Peers
Comparison fields: 5 of 99
- Infectious Diseases 308
- Pulmonary and Respiratory Medicine 454
- Cancer Research 198
- Neurology 161
- Critical Care and Intensive Care Medicine 47
Countries citing papers authored by Xiaofan Lu
This map shows the geographic impact of Xiaofan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofan Lu more than expected).
Fields of papers citing papers by Xiaofan Lu
This network shows the impact of papers produced by Xiaofan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofan Lu. The network helps show where Xiaofan Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaofan Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19 Hit paper breakdown → | 2020 | 367 |
| 2 | 2019 | 161 | |
| 3 | 2020 | 136 | |
| 4 | 2020 | 89 | |
| 5 | 2020 | 59 | |
| 6 | 2020 | 53 | |
| 7 | 2021 | 47 | |
| 8 | 2021 | 47 | |
| 9 | 1993 | 33 | |
| 10 | 2007 | 33 | |
| 11 | 2021 | 31 | |
| 12 | 2020 | 29 | |
| 13 | 2023 | 28 | |
| 14 | 2020 | 26 | |
| 15 | 2018 | 26 | |
| 16 | 2022 | 26 | |
| 17 | 2018 | 24 | |
| 18 | 2018 | 24 | |
| 19 | 2020 | 21 | |
| 20 | 2011 | 18 |
About Xiaofan Lu
Xiaofan Lu is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Surgery and Molecular Biology, having authored 71 papers that have together received 1.6k indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (10 papers), Epigenetics and DNA Methylation (8 papers), Renal and related cancers (7 papers), Bladder and Urothelial Cancer Treatments (6 papers), Renal cell carcinoma treatment (6 papers), RNA modifications and cancer (5 papers), Cancer-related molecular mechanisms research (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Infectious Diseases (308 citations), Pulmonary and Respiratory Medicine (454 citations), Cancer Research (198 citations), Neurology (161 citations) and Critical Care and Intensive Care Medicine (47 citations). Xiaofan Lu has collaborated with scholars based in China, United States and France. Frequent co-authors include Fangrong Yan, Yang Wang, Taige Chen, Jun Wang, Jialin Meng, Liyun Jiang, Yujie Zhou, Bing Zhang, Yongsheng Li and Jing Zhou. Their work appears in journals such as Clinical and Translational Medicine, Cell Proliferation, Critical Care, Blood and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.